Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is a young, yet well-equipped neuropsychiatric biopharmaceutical company. Its lead asset, LB-102, has shown statistically significant improvement in both positive and cognitive symptoms for schizophrenia patients, and its Phase 2 trial for bipolar depression is designed for success. Additionally, LB's strong IP portfolio and focus on the growing long-acting injectable market make it a strong investment opportunity.

Bears say

LB Pharmaceuticals is facing a number of challenges, including competition within the highly litigious pharmaceutical industry, potential difficulties in defending its intellectual property claims, and the need to generate significant cash flows in order to become profitable given the high costs associated with developing and bringing a new drug to market. Additionally, the potential for generic competition and downward pressure on branded product sales in maintenance settings could impact eventual revenue potential. While the company's pipeline shows promise, there may be uncertainty and risk involved in successfully navigating the clinical trial process and obtaining FDA approval for its lead drug, LB-102.

LBRX has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Buy based on their latest research and market trends.

According to 7 analysts, LBRX has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.